CD3D and PRKCQ work together to discriminate between B-cell and T-cell acute lymphoblastic leukemia. (1st October 2016)

• Record Type: Journal Article
• Authors: Ma, Dongli; Zhong, Shan; Liu, Xiaorong; Mai, Huirong; Mai, Guoqin; Xu, Cheng; Zhou, Fengfeng
• Is Part Of: Computers in biology and medicine. Volume 77(2016)
• Page Start: 16
• Page End: 22
• Publication Date: 2016-10-01
• Subjects: ALL acute lymphoblastic leukemia -- B-ALL B-cell ALL -- T-ALL T-cell ALL; Acute lymphoblastic leukemia -- Biomarker -- CD3D -- PRKCQ -- B-ALL -- T-ALL; Medicine -- Data processing -- Periodicals; Biology -- Data processing -- Periodicals; 610.285
• DOI: 10.1016/j.compbiomed.2016.07.004
• Languages: English
• ISSNs: 0010-4825

Abstract

Abstract: Different therapeutic methods have been developed for the B-cell and T-cell subtypes of acute lymphoblastic leukemia (ALL). The identification of molecular biomarkers that can accurately discriminate between B-cell and T-cell ALLs will facilitate the quick determination of therapeutic plans, as well as reveal the intrinsic mechanisms underlining the two different ALL subtypes. This study computationally screened the high-throughput transcriptome dataset for multiple candidate biomarkers and verified their discrimination abilities in an independent sample set using quantitative real-time polymerase chain reaction (PCR) technology. Both technologies suggest that the two genes CD3D and PKRCQ together provided a good model for classification of B-cell and T-cell ALLs, whereas the individual genes did not show consistent discrimination between the two ALL subtypes. Supplementary material is available athttp://healthinformaticslab.org/supp/ . Highlights: Two-gene biomarker to discriminate B-cell and T-cell acute lymphoblastic leukemia. Integration of both computational and experimental technologies. Transmembrane antigen CD3D and kinase PRKCQ may serve as stable treatment targets.